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BACKGROUND. Nod1 and Nod2 are cytosolic receptors which are responsible for sensing
bacterial peptidoglycan derivatives. In this study, we determined whether Nod1 and Nod2
are involved in the innate immune responses of prostate epithelial cells.
METHODS. The expression of Nod1 and Nod2 was examined by RT-PCR and immunohis-
tochemistry. ELISA was performed to determine the production of cytokines/chemokines.
Activation of NF-kB and MAPK was examined using western blot analysis.
RESULTS. The Nod1 gene was distinctly expressed in all tested cells including DU145, PC3,
and TRAMP-C2 cells, whereas Nod2 expression was weak. Both Nod1 and Nod2 proteins
were expressed in normal mouse prostate epithelia with difference of expression levels. Tri-
DAP (Nod1 agonist), but not MDP (Nod2), increased the production of IL-8 (or KC) and IL-6
in prostate epithelial cells. Tri-DAP and MDP could upregulate the gene expression of COX-2
and activate NF-kB and MAPK. In addition, Tri-DAP and MDP synergized with TLR agonists
to induce the production of IL-8/KC or IL-6 in PC3 and TRAMP-C2 cells. We finally showed
that Nod1 and Nod2 were also expressed in a wide range of prostate lesions including pros-
tate intraepithelial neoplasm (PIN), phyllodes-like tumor, and adenocarcinoma in TRAMP
(transgenic adenocarcinoma of the mouse prostate) mice, even though the expression level of
Nod1 and Nod2 was different.
CONCLUSION. These results indicate that Nod1 and Nod2 may play important roles in the
innate immune response of prostate epithelial cells and the development and progression of
prostate cancer. Prostate 72:1351–1358, 2012. # 2012 Wiley Periodicals, Inc.
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cyclooxygenase-2
INTRODUCTION
The detection of microbial products by pattern rec-
ognition receptors (PRRs) such as Toll-like receptors
(TLRs) and Nod-like receptors (NLRs) initiates innate
immune responses, which play a critical role in host
defense against invading pathogens. TLRs recognize
conserved microbial molecules including lipopro-
teins, LPS, flagellin, and nucleic acids at the cell sur-
face or endosomal membrane [1]. In addition, TLRs
also sense various endogenous ligands including heat
shock proteins (Hsp), fibronectin, and high mobility
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group box-1 (HMGB-1) and are involved in various
human diseases [2–3].
NLRs are another family of PRRs that mediate the
cytosolic recognition of microbial molecules. NLRs
consist of an N-terminal effector domain including a
caspase recruitment domain (CARD) or a pyrin N-
terminal homology domain (PYD); a central nucleo-
tide-binding oligomerization domain (Nod); and a
putative C-terminal pathogen-sensing domain con-
sisting of leucine-rich repeats (LRR) [4]. There are 23
NLR family members in humans, and at least 34 genes
in mice [5]. NLRs are expressed in nonimmune cells
including epithelial cells and mesothelial cells and in
immune cells [6–7]. The first identified NLRs were
Nod1 and Nod2, which recognize meso-diaminopimelic
acid (meso-DAP) and muramyl dipeptide (MDP), the
derivatives of bacterial peptidoglycans, respectively
[4]. After recognition, Nod1 and Nod2 associate
with a serine/threonine kinase, RICK/Rip2, via a
CARD–CARD interaction, subsequently leading to
NF-kB activation and the production of inflammatory
mediators [8]. In addition, Nod2 can recognize
viral ssRNA and initiate innate immune antiviral
responses by producing IFN-b through IRF3 activa-
tion [9].
The prostate is associated with various pathologi-
cal conditions such as chronic inflammation, benign
hyperplasia, and cancer. Prostatitis is the most com-
mon urologic syndrome in men younger than 50 years
of age [10] and affects 11–16% of American men
[11–12]. Although the majority prostatitis cases are
not associated with bacterial infection, a small portion
of prostatitis cases are due to acute or chronic bacteri-
al infection [13]. According to the NIH classification
of prostatitis, Class I and II cases are associated with
bacterial infection [14–15]. Class I corresponds to
acute bacterial prostatitis with a uropathogen, often
with systemic symptoms of fever, chills, and hypoten-
sion. Class II corresponds to chronic bacterial prostati-
tis. Gram-negative bacteria such as E. coli, Klebsiella,
and Pseudomonas are predominantly responsible for
chronic bacterial prostatitis [13,16]. Host immune
responses against microbial infection are closely asso-
ciated with tumor development and progression as
well as inflammation in the prostate. Therefore, it is of
therapeutic value to understand the mechanisms
responsible for the host immune response in the pros-
tate. Although several studies have revealed the
involvement of TLRs in the immune responses of
prostate epithelial cells [17–19], little is known about
whether Nod1 and Nod2 contribute to the innate
immune responses of prostate epithelial cells. In this
study, we examined the expression and immunologi-
cal function of Nod1 and Nod2 in human and mouse
prostate epithelial cells and tissues.
MATERIALSANDMETHODS
CellCulture andReagents
The DU145, PC3 (human origin), and TRAMP-C2
(mouse origin) prostate epithelial cells lines were pur-
chased from ATCC (Rockville, MD). DU145 and PC3
cells were incubated in RPMI medium containing 10%
fetal bovine serum (FBS) and 1  penicillin/strepto-
mycin at 378C in a 5% CO2 atmosphere. TRAMP-C2
cells were incubated in DMEM medium containing
10% FBS, 1  penicillin/streptomycin, 5 mg/ml bo-
vine insulin, 10 nM dehydroisoandrosterone, and 5%
Nu-Serum IV at 378C in a 5% CO2 atmosphere. Tri-
DAP, ultrapure LPS from E. coli O111:B4, and
Pam3CSK4 were purchased from InvivoGen (San
Diego, CA). MDP [Ac-(6-O-stearoyl)-muramyl-Ala-D-
Glu-NH2] was purchased from Bachem (Torrance,
CA). Mouse bone marrow derived macrophages
(BMDMs) were prepared as previously described
[20].
Animals
Six weeks old male C57BL/6 mice were obtained
from Orient Bio (Seongnam, Kyounggi-do, Korea)
and used for immunohistochemistry on normal
mouse prostate. As mouse prostate tumor model,
TRAMP (transgenic adenocarcinoma of the mouse
prostate) mice were purchased from The Jackson
Laboratories (Bar Harbor, ME). TRAMP hemizygote
mice (female) were mated with WT mice on C57BL/6
background. Animal experiment was approved and
followed by the regulations of the Institutional Ani-
mal Care and Use Committee in Konyang University.
RNAExtractionandReverseTranscription-
PolymeraseChainReaction (RT-PCR)
Total RNA was extracted from each cell using
easy-BLUE (Intron biotechnology, Daejeon, KOREA)
according to the manufacturer’s instruction. One mi-
crogram of total RNA was reverse transcribed into
cDNA, and PCR was performed using the Power
cDNA Synthesis Kit (Intron biotechnology) and One-
step RT-PCR with AccuPower1 HotStart PCR PreMix
(Bioneer, Daejeon, Korea). The following primer sets
were used.
human Nod1, F: 50-CCACTTCACAGCTGGAGACA-30
R: 50-TGAGTGGAAGCAGCATTTTG-30
human Nod2, F: 50-GAATGTTGGGCACCTCAAGT-30
R: 50CAAGGAGCTTAGCCATGGAG-30











mouse Nod1, F: 50-AGCTGCAGCCTTGCTTTAGCC-30
R: 50-TCAGCCATAAATGCCGTAGCG-30
mouse Nod2, F: 50-CCGAAGCCCTAGCACTGATGC-30
R: 50-CAACCATCACGACTCCTCGGG-30
mouse b-actin, F: 50-ATGGATGACGATATCGCT -30
R: 50-ATGAGGTAGTCTGTCAGGT -30




The PCR conditions consisted of 1 cycle of 948C for
5 min; 35 cycles of 948C for 30 sec, 56–608C for 30 sec,
and 728C for 30 sec; and 1 cycle of 728C for 10 min.
PCR products were then electrophoresed on a 1.5%
agarose gel and visualized using a gel documentation
system.
Immunohistochemistry
Urogenital tissues including urinary bladder, semi-
nal vesicle, and prostate were removed, fixed in 10%
formalin over 24 hr, and processed in standard
alcohol–xylene series. The tissues were embedded in
paraffin and 3 mm sections were prepared. They were
treated with 0.3% hydrogen peroxide (H2O2) in PBS
for 30 min and 10% normal goat serum in PBS for
30 min for blocking. Subsequently, the sections were
incubated with diluted rabbit isotype IgG, anti-Nod1,
and anti-Nod2 (1:200; Imgenex, San Diego, CA) over-
night at room temperature and subsequently exposed
to biotinylated goat anti-rabbit IgG and streptavidin
peroxidase complex (Vector, Burlingame, CA). Then,
the sections were visualized with 3,30-diaminobenzidine
in 0.1 M Tris–HCl buffer and counterstained with
methyl green (Sigma, St. Louis, MO).
Measurementof IL-6 and IL-8/KC
The cells were treated with the indicated doses
of Tri-DAP and MDP for 24 hr, and the culture
supernatant was collected. The concentrations of IL-6
and IL-8 (or KC for TRAMP -C2 cells) in the culture
supernatants were determined using a commercial
enzyme-linked immunosorbent assay (ELISA) kit
(R&D System).
WesternBlotAnalysis
The cells were lysed in buffer containing 1% Nonidet-
P40 supplemented with a complete protease
inhibitor cocktail (Roche) and 2 mM dithiothreitol.
Lysates were resolved by 10% SDS–PAGE, transferred
to a polyvinylidene fluoride (PVDF) membrane, and
immunoblotted with primary antibodies against
IkB-a, phospho-IkB-a, p38, ERK, and JNK (Cell
signaling, Beverly, MA). After immunoblotting with
secondary antibodies, proteins were detected with an
enhanced chemiluminescence (ECL) reagent (Intron
Biotechnology).
StatisticalAnalysis
The differences among the mean values of the dif-
ferent groups were tested, and the values were
expressed as the mean  SD. All of the statistical
calculations were performed by one-way ANOVA
followed by the Bonferroni post-hoc test for multi-
group comparisons using GraphPad Prism version
5.01 (GraphPad Software, San Diego, CA). Values of




The gene expression of Nod1 and Nod2 was exam-
ined in both human and mouse prostate epithelial
cells lines using RT-PCR. The Nod1 gene was
markedly expressed in both DU145 and PC3 cells,
whereas the gene expression of Nod2 was very weak
in DU145 cells and undetectable in PC3 cells
(Fig. 1A). However, stimulation with MDP, a Nod2-
specific agonist, augmented Nod2 expression in PC3
Fig. 1. The gene andprotein expression levels ofNod1andNod2
in prostate epithelial cells andmouseprostate.ThemRNAexpres-
sion levels of Nod1, Nod2, and GAPDH/b-actin were examined in
human prostate epithelial cell lines (DU145 and PC3) (A) and in a
mouseprostate epithelialcell line (TRAMP-C2) andmouseBMDMs
(C) by RT-PCR. In PC3 cells, Nod2 expression levels were deter-
minedby RT-PCR 2 hr after stimulationwith or withoutMDP (B).




cells (Fig. 1B). In addition, TRAMP-C2 mouse prostate
epithelial cells also exhibited distinct gene expression
of Nod1, the level of which was comparable to that in
mouse BMDMs (Fig. 1C). The Nod2 gene was also de-
tectable in TRAMP-C2 cells, but its expression level
was relatively weak (Fig. 1C). Finally, we determined
the protein expression of Nod1 and Nod2 in mouse
prostate tissue. There was no signal in the isotype-
IgG-treated section (Fig. 1D). However, both Nod1
and Nod2 expressions were detectable in the cyto-
plasm of prostate epithelia, but not stroma (Fig. 1D).
In accordance with in vitro results, the intensity of
Nod1 was much stronger than that of Nod2 (Fig. 1D).
Nod1butnotNod2StimulationEnhancedIL-8(orKC)
and IL-6ProductioninProstateEpithelialCells
To determine whether stimulation of Nod1 and
Nod2 leads to the production of proinflammatory
cytokines/chemokines, the cells were treated with
Tri-DAP (Nod1 agonist) and MDP (Nod2 agonist),
and the amount of IL-8 (or its mouse homologue, KC)
and IL-6 secreted into the culture supernatant was
determined by ELISA. Tri-DAP, but not MDP, led to
an increase in IL-8 production by PC3 and DU145
cells (Fig. 2A,B). IL-6 production was also increased
by Tri-DAP in PC3 cells in a dose-dependent manner
(Fig. 2C). However, Tri-DAP did not enhance IL-6
production in DC145 cells (Fig. 2D). In TRAMP-C2
cells, the levels of KC and IL-6 were also upregulated
by Tri-DAP in a dose-dependent manner (Fig. 2E,F).
Similar to the result for PC3 and DU145 cells, MDP
did not affect the production of KC or IL-6 in
TRAMP-C2 cells (Fig. 2E,F).
Tri-DAPandMDPasWellasLPSInducetheGene
ExpressionofCyclooxygenase-2 inPC3Cells
We next sought to determine the effects of Nod1
and Nod2 activation on the gene expression of COX-2
in prostate epithelial cells. The results showed that
Tri-DAP, MDP, and LPS could induce COX-2 mRNA
expression in PC3 cells with different kinetics (Fig. 3).
The gene expression of COX-2 induced by Tri-DAP
was maximal 2 hr after stimulation, whereas MDP-
induced COX-2 expression was maximal 4 hr post-
stimulation (Fig. 3). As a positive control, LPS also led
to the induction of COX-2 expression (Fig. 3), albeit




To determine whether Nod1 and Nod2 stimulation
leads to NF-kB and MAPK activation in prostate
epithelial cells, PC3 cells were treated with Tri-DAP
or MDP, and extracts were prepared at different times
after stimulation. Subsequently, immunoblotting was
performed using antibodies that recognize activated
forms of NF-kB, p38, JNK, and ERK. The results
showed that Tri-DAP and MDP induced the phos-
phorylation of p38, ERK, JNK, and IkB-a (Fig. 4A,B),
although the kinetics were different between Tri-DAP
and MDP. At 15 min after stimulation, both Tri-DAP
Fig. 2. The production of IL-8 or its mouse homolog, KC, and
IL-6byprostate epithelialcells inresponse toTri-DAPandMDP.The
cells (2  104/well in a 48-wellplate)were stimulatedwith the indi-
cateddoses ofTri-DAPorMDP for24 hr, and the IL-8 (A andB)/KC
(E) and IL-6 (C,D, and F) levels in the culture supernatant were
determinedusing a commercial ELISAkit.The results are fromone
representative experiment of three independent experiments
and are presented as the mean  SD. P < 0.05,  P < 0.01, 
P < 0.001.
Fig. 3. COX-2 expression in PC3 cells in response to Nod1,
Nod2, and TLR agonists. The cells were treated with Tri-DAP
(10 mg/ml), MDP (10 mg/ml), or LPS (1 mg/ml) for the indicated
times, and COX-2 expression was determined by RT-PCR. The




and MDP induced the phosphorylation of IkB-a.
However, Tri-DAP induced prolonged IkB-a phos-
phorylation compared to MDP stimulation. In addi-
tion, Tri-DAP induced optimal activation of p38 and
JNK at 15 min, whereas MDP induced at p38 and
JNK activation at 120 and 60 min after stimulation,
respectively (Fig. 4A,B). Similar levels of ERK phos-
phorylation were detected at 15 and 30 min after
stimulation with either Tri-DAP or MDP (Fig. 4A,B).
Nod1andNod2SynergyWithTLRsto Induce
theProduction IL-6 and IL-8/KCin
ProstateEpithelialCells
Dose-response experiments were performed to
determine an appropriate dose of Pam3CSK4 (TLR2
agonist) and LPS (TLR4 agonist) to be used in the
synergism experiment. The results revealed that
100 ng/ml of Pam3CSK4 and 1 mg/ml of LPS led to
minor increases in IL-6 production in PC3 cells (data
not shown), and these doses were used in the subse-
quent experiments. For the synergism experiment,
PC3 cells were treated with the indicated agonist
alone or in combination for 24 hr, and the IL-6 and IL-
8 production levels were measured using the culture
supernatant. As shown in Figure 5A,B, the combina-
tion treatment with Tri-DAP and TLR agonists
(Pam3CSK4 or LPS) significantly enhanced IL-6 and
IL-8 production in PC3 cells compared with treatment
with the agonists alone. MDP also enhanced the IL-8
production induced by Pam3CSK4 or LPS in PC3 cells
(Fig. 6C), although MDP itself did not induce the pro-
duction of IL-8. In TRAMP-C2 cells, Tri-DAP and
MDP also augmented the IL-6 production induced by
Pam3CSK4 or LPS (Fig. 6D,E).
TheExpressionofNod1andNod2 inProstate
TumorofMice
To determine the protein expression of Nod1 and
Nod2 in mouse prostate tumor, immunohistochemis-
try was performed in the prostate tissue of TRAMP
and age-matched WT mice (24 weeks old). Likely
with Figure 1D, Nod1 and Nod2 were broadly
expressed in the prostate epithelia of WT mice
(Fig. 6A–D). A wide range of prostate lesions includ-
ing low, moderate, and high-grade prostatic intraepi-
thelial neoplasia (PIN), phyllodes-like tumor, and
well-to-poorly differentiated adenocarcinoma were
observed in TRAMP mice (data not shown). Nod1
and Nod2 were mainly expressed in glandular epithe-
lial cells of high-grade PIN (E–H) or epithelia overlay-
ing the stroma of the phyllodes-like tumor (Fig. 6I–L).
Likely in normal mouse prostate, the intensity of
Nod1 was much stronger than that of Nod2 (Fig. 6E–L).
These phenomena were also observed in well-to-
poorly differentiated adenocarcinoma (data not
shown). In glandular muscularis or the stroma of
tumor, both Nod1 and Nod2 expressions were very
weak (Fig. 6E–L). We also compared the gene expres-
sion of Nod1 and Nod2 between normal prostate
(from age-matched WT mice) and prostatic tumor
(from TRAMP mice). As shown in Figure 6M, mRNA
of Nod1 in normal and tumor tissues of prostate was
as strong as that in spleen and there was no difference
of the intensity between two groups (normal tissues
vs. tumor). Nod2 expression was very weak in both
normal and tumor tissues, as compared with that in
Fig. 4. NF-kB and MAPK activation in PC3 cells in response to
Tri-DAP and MDP.The cells were stimulated with10 mg/ml of Tri-
DAP (A) or MDP (B), and protein was extracted at the indicated
time points. IkB-a degradation and the phosphorylation of IkB-a,
p38, JNK, and ERKwere examinedby western blotting. A primary
antibodyagainst theall formsofERKwasusedtoconfirmtheloaded
proteindoses.Theresults are fromonerepresentative experiment
of twoindependentexperiments.
Fig. 5. SynergismofNLR andTLR agonists for IL-6 and IL-8 pro-
duction in prostate epithelial cells. PC3 (A^C) and TRAMP-C2 (D
and E) cells were treatedwith the indicated agonist alone or their
combination for 24 hr, and the IL-6 (A,D, andE) and IL-8 (B andC)
production levels weremeasured in the culture supernatant using
ELISA.Theresultsare fromonerepresentativeexperimentof three
independent experiments and are presented as the mean  SD.
P < 0.05,P < 0.01,P < 0.001.
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spleen (Fig. 6M). However, there seemed to be indi-
vidual difference in the gene expression of Nod2 in
mouse prostate. Nod2 expression in prostate was
detectable in only two of three mice in each group,
which prevents to compare the gene expression of
Nod2 between the prostates of WT and TRAMP mice.
To make a decision for the alteration of Nod2 expres-
sion on tumor progression of prostate, further study
should be performed using the increasing number of
mice.
DISCUSSION
Local epithelial cells are the first line of defense
against microbial infection. In addition to providing a
physical barrier, epithelial cells can initiate the host
defense system by producing cytokines, chemokines,
or antimicrobial peptides. Several TLRs have been
found to contribute to immune responses in prostate
epithelial cells. TLR4 regulates the expression of
VEGF and TGF-b1 in human prostate epithelial cells
in response to LPS [17]. Mycoplasma hominis infection
leads to IL-8 secretion in prostate epithelial cells
through a TLR2-dependent mechanism [18]. In addi-
tion, TLR9 agonist CpG oligonucleotides (ODNs) pro-
mote inflammatory cytokines and upregulate the
expression of COX-2 via NF-kB activation in prostate
epithelial cells [19,21]. Although various epithelial
cells in the skin, kidney, liver, stomach, and oral
cavity functionally express Nod1 and Nod2 [7,22–25],
the expression levels and function of Nod1 and Nod2
in prostate epithelial cells have not been clearly
defined.
In this study, we first examined the gene expres-
sion of Nod1 and Nod2 in human (PC3 and DU145)
and mouse (TRAMP-C2) prostate epithelial cells.
Nod1 was distinctly expressed in both human and
mouse prostate epithelial cell lines, whereas Nod2
expression was relatively weak in DU145 and
TRAMP-C2 cells and undetectable in PC3 cells. In ad-
dition, the protein of Nod1 and Nod2 was detectable
in the cytoplasm of normal prostate epithelia in vivo,
although the intensity of Nod1 was much stronger
than that of Nod2. Nod1 mRNA has been reported to
be strongly expressed in various types of epithelial
cells [7,22–23,26]. However, the expression level of
Nod2 was different between cell types. The mRNA
and protein of Nod2 was markedly expressed in
hepatocytes, oral epithelial cells, and renal tubular
epithelial cells [7,22–23] but was not expressed or was
weakly expressed in intestinal epithelial cells [27]. In
addition, Nod2 expression seems to be regulated by
specific treatment. Treatment with bacterial flagellin
(a TLR5 agonist), E. coli, and IL-1b could upregulate
the gene expression of Nod2 in intestinal epithelial
cells [27]. Furthermore, in the presence of histamine,
MALP-2 (a TLR2 agonist), peptidoglycan, and b-
glucan also enhanced Nod2 gene expression in kerati-
nocytes [28]. In our study, the gene expression of
Nod2 was also upregulated by MDP in PC3 cells. It is
likely that Nod1 is constitutively expressed, but Nod2
expression is inducible under specific conditions in
prostate epithelial cells. In fact, in this study, there
was no difference on the gene expression of Nod1
between normal prostate and prostatic tumor.
IL-8 is a proinflammatory CXC chemokine that has
a key role in the recruitment and activation of neutro-
phils during inflammation. IL-6 is a multifunctional
inflammatory cytokine that regulates chronic inflam-
mation and can create a cellular microenvironment
beneficial to cancer growth [29–30]. Prostate epithelial
cells can produce IL-8 and IL-6 in response to bacteri-
al infections with microbes such as Propionibacterium
and Mycoplasma [18,31]. To determine whether Nod1
and Nod2 can promote the production of proinflam-
matory cytokines or chemokines in prostate epithelial
cells, we examined IL-8/KC and IL-6 production in
PC3, DU145, and TRAMP-C2 cells in response to Tri-
DAP and MDP. Tri-DAP induced IL-6 and IL-8/KC
production in all cell lines tested. However, MDP did
not increase IL-8 or IL-6 production in the cells. This
result is in accordance with previous studies showing
that MDP alone did not induce the production of
proinflammatory cytokines or chemokines in most
Fig. 6. (Originalmagnification) The gene andprotein expression
of Nod1andNod2 in the prostate ofWTand TRAMPmice. Immu-
nohistochemistry was performed to determine the expression of
Nod1 and Nod2 in prostate of WT (age-matched) (A^D) and
TRAMP (32weeks old) (E^L)mice.G,H,K, andLwere at100 of
magnification and others are at 400. RNAwas extracted from
the prostates of three mice in each group (WT and TRAMP;




epithelial cells except those of intestinal origin
[7,26,32]. Furthermore, in immune cells such as mouse
BMDMs, MDP alone did not induce the production of
cytokines such as IL-6 and TNF-a, even though MDP
can induce NF-kB and MAPK activation [33]. In this
study, MDP and Tri-DAP led to NF-kB and MAPK
activation in PC3 cells, although with distinct kinetics.
These findings suggest that Nod1 and Nod2 are
expressed and may contribute to triggering immune
response in prostate epithelial cells.
Cyclooxygenase is a key enzyme catalyzing the
rate-limiting step of prostaglandin biosynthesis from
arachidonic acid. There are three isoforms; COX-1 is a
constitutive form, COX-2 is an inducible form, and
COX-3 is present mainly in the brain and spinal cord
[34]. Among these three proteins, COX-2 has been
found to be correlated with prostate tumor growth
and angiogenesis [35]. Moreover, COX-2 can directly
promote cellular invasion in prostate cancer and the
inhibition of COX-2 leads to decreased tumor cell
invasiveness [36–37]. In this study, we revealed that
the stimulation of Nod2 and Nod1 can induce the
gene expression of COX-2 in PC3 cells. It remains to
be clarified whether Nod1 and Nod2 are involved in
aspects of tumor progression such as angiogenesis
and invasiveness in prostate cancer.
Previous studies have shown that Nod1 and Nod2
have synergistic or additive effects with TLRs with
respect to the production of cytokines and chemo-
kines in immune cells and mesothelial cells [6,33,38].
These phenomena were also observed in epithelial
cells. In oral epithelial cells, Nod1 and Nod2 agonists
in combination with TLR agonists synergistically en-
hanced b-defensin 2 secretion [32]. Moreover, LPS
pretreatment enhanced the activation of NF-kB, ERK,
and JNK by MDP in hepatocytes [7]. Likewise, in this
study, Nod1 and Nod2 agonists (Tri-DAP and MDP)
synergized with TLR agonists (Pam3CSK4 or LPS) to
induce the production of IL-8 or IL-6 in PC3 and
TRAMP-C2 cells. Our results indicate that Nod1 and
Nod2 may cooperate with TLRs to elicit immune
responses in prostate epithelial cells.
CONCLUSION
Inflammation is crucial for the etiology of prostate
cancer. TLRs (other family of PRRs) activation is
known to promote tumorigenic events such as cell
proliferation, angiogenesis, metastasis, and immune
suppression in various cancers including prostate
cancer. Likely with TLRs, in the present study, we
revealed that Nod1 and Nod2 are functionally
expressed in human and mouse prostate epithelial
cells and that the activation of those receptors can
induce innate immune responses such as cytokine
production, COX-2 expression, and the activation of
NF-kB and MAPK. These findings indicate that Nod1
and Nod2 signaling may participate in the develop-
ment and progression of prostate cancer, even though
the gene expression of Nod1 and Nod2 was not
changed in mouse prostatic tumors. Therefore, it is
necessary to clarify whether Nod1 and Nod2 activa-
tion affects the cell proliferation, metastasis, or im-
mune suppression in prostate cancers.
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